Physician profile
Arzu Hatipoglu
NPI 1396748828
$3,584.57
in general payments reported to CMS, 2019-2025
18 companies · $723 in 2025
The $723 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $197 · 2021: $221 · 2022: $518 · 2023: $713 · 2024: $724 · 2025: $723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,135 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,135.46 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $587.52 | 2020-2025 | Krystexxa, Tavneos |
| Aurinia Pharma U.S., INC. | $450.31 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals Lp | $350.61 | 2020-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $307.98 | 2019-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $295.23 | 2023-2025 | Acthar |
| Calliditas Therapeutics US INC. | $257.55 | 2024-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $246.87 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $246.46 | 2022-2024 | |
| Vifor Pharma, INC. | $200.49 | 2019-2025 | Veltassa, Korsuva |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $169.98 | 2022-2025 | Voyxact |
| Horizon Therapeutics Plc | $136.83 | 2023 | Krystexxa |
| Akebia Therapeutics INC | $116.14 | 2019-2025 | Vafseo, Auryxia |
| Nxstage Medical, INC. | $73.16 | 2019 | |
| Rockwell Medical, INC. | $60.60 | 2019 | |
| Travere Therapeutics, INC. | $22.93 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $21.95 | 2021 | |
| Cormedix INC. | $20.46 | 2024 | Defencath |
| Lilly USA, LLC | $19.50 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arzu Hatipoglu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.